药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Rescinnamine
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Panobinostat.
Rescinnamine
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Panobinostat.
Rescinnamine
Interferon alfa
The risk or severity of adverse effects can be increased when Interferon alfa is combined with Panobinostat.
Rescinnamine
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Panobinostat.
Rescinnamine
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Panobinostat.
Rescinnamine
Brequinar
The risk or severity of adverse effects can be increased when Brequinar is combined with Panobinostat.
Rescinnamine
2-Methoxyethanol
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Panobinostat.
Rescinnamine
Castanospermine
The risk or severity of adverse effects can be increased when Castanospermine is combined with Panobinostat.
Rescinnamine
Stepronin
The risk or severity of adverse effects can be increased when Stepronin is combined with Panobinostat.
Rescinnamine
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Panobinostat.
Rescinnamine
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Panobinostat.
Rescinnamine
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Panobinostat.
Rescinnamine
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.
Podofilox
Berotralstat
The serum concentration of Pazopanib can be increased when it is combined with Berotralstat.
Podofilox
Filgotinib
The serum concentration of Pazopanib can be increased when it is combined with Filgotinib.
Podofilox
Satralizumab
The serum concentration of Pazopanib can be decreased when it is combined with Satralizumab.
Podofilox
Abametapir
The serum concentration of Pazopanib can be increased when it is combined with Abametapir.
Podofilox
Inebilizumab
The risk or severity of infection can be increased when Pazopanib is combined with Inebilizumab.
Podofilox
Selpercatinib
The serum concentration of Pazopanib can be increased when it is combined with Selpercatinib.
Podofilox
Capmatinib
The serum concentration of Pazopanib can be increased when it is combined with Capmatinib.